Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Raw Materials (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Raw Materials data on record, last reported at $202000.0 in Q4 2025.

  • For Q4 2025, Raw Materials fell 5.61% year-over-year to $202000.0; the TTM value through Dec 2025 reached $202000.0, down 5.61%, while the annual FY2025 figure was $202000.0, 5.61% down from the prior year.
  • Raw Materials reached $202000.0 in Q4 2025 per OCUL's latest filing, down from $229000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $388000.0 in Q4 2021 and bottomed at $187000.0 in Q1 2025.
  • Average Raw Materials over 5 years is $288400.0, with a median of $305500.0 recorded in 2022.
  • Peak YoY movement for Raw Materials: soared 86.5% in 2021, then tumbled 43.16% in 2025.
  • A 5-year view of Raw Materials shows it stood at $388000.0 in 2021, then decreased by 20.36% to $309000.0 in 2022, then fell by 2.27% to $302000.0 in 2023, then dropped by 29.14% to $214000.0 in 2024, then decreased by 5.61% to $202000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $202000.0 in Q4 2025, $229000.0 in Q3 2025, and $219000.0 in Q2 2025.